Interstitial Cystitis Drugs Market by Type, Distribution Channel and Geography - Forecast and Analysis 2023-2027

Published: Jan 2023

Pages: 160

SKU: IRTNTR45643

Snapshot

The Global Interstitial Cystitis (IC) Drugs market size is estimated to grow by USD 369.58 million and the size of the market is estimated to accelerate at a CAGR of 5.9% between 2022 and 2027. Awareness of interstitial cystitis, the advent of gene therapy, advancement in drug, and the increasing approval of drugs is helping fight interstitial cystitis disease. Furthermore, the increasing grants for research on interstitial cystitis are also notably driving market growth. The global interstitial cystitis drugs market is dominated by Johnson and Johnson Inc., Vitaris Inc., Bayer AG, Pfizer Inc., and Sun Pharmaceutical Industries Ltd., among others. The drugs offered by these companies are small molecules and have proven efficacy, which helps these vendors maintain their dominant positions in the market. Vendors in key regions such as North America and Europe are flourishing since many people are dealing with interstitial cystitis disease in these regions. Not only in North America and Europe but also vendors in China and India will also probably lead the interstitial cystitis drugs market in Asia during the forecast period, owing to the development of the healthcare segment.

Technavio has divided the global interstitial cystitis (IC) drugs market into three segments that are Type, Distribution Channel, and Geography.

The type segment is classified into oral therapy and intravesical therapy.
The Distribution channel segment is classified into hospital pharmacies, retail pharmacies, and online pharmacies.
The Geography segment includes key regions such as North America, Europe, Asia, and the Rest of World (ROW).

It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the Size of the Interstitial Cystitis Drugs Market During the Forecast Period?

To learn more about this report, Download the FREE Report Sample

Interstitial Cystitis Drugs market segmentation by Type, Distribution Channel, and Geography

Type Analysis

The type segmentation is divided into two categories that are oral therapy and intravesical therapy. The oral therapy segment was valued at USD 586.82 million in 2017 and continues to grow during the forecast period.

Get a glance at the market contribution of various segments Request a PDF Sample

Pentosan polysulfate sodium (ELMIRON) is the only approved oral medication to repair the lining of the bladder in people with interstitial cystitis (IC). ELMIRON builds and restores the protective coating of the bladder tissue. It can also reduce the swelling of the bladder. Glycosaminoglycan (GAG layer) is composed of a coating of mucus, which protects the bladder wall from bacteria and irritating substances in the urine. There are many off-label oral drugs in the global interstitial cystitis drugs market that can reduce the signs and symptoms of the disease. For instance, in the management of bladder pain, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen are widely used. Thus, the demand for oral therapy will drive the growth of the market in focus during the forecast period.

Distribution Channel

Hotel pharmacies are leading the market during the forecast period. Hospital pharmacies comprise pharmaceuticals that are purchased directly by hospitals from different pharmaceutical companies and used for the treatment of either outpatients or inpatients. The drugs that are found in hospital pharmacies include therapeutic and critical care drugs. The primary aim of hospital pharmacies is to procure, store, and sell medications to patients in hospitals. Hospital pharmaceuticals are administered to individuals during the hospital-enabled treatment period. More hospitals are consolidating into larger healthcare systems, which can include payors, specialty services, outpatient clinics, long-term care facilities, and physician practices. This, in turn, will drive the growth of the market focus during the forecast period.

To know more about segments download the sample reports

Regional Analysis

North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request PDF Sample now!

North America accounted for the largest share of the global IC drugs market, primarily due to the increasing cases of interstitial cystitis in the region. A rise in research funding will also contribute to the growth of the market in the region during the forecast period. Furthermore, the US Food and Drug Administration (FDA) approved ELMIRON and RIMSO-50 for the treatment of interstitial cystitis. These two drugs hold major market shares in this region as they have a better safety profile compared with off-label drugs. Moreover, there are no generics available currently for these approved drugs in the US. Hence, the market in North America will grow with the sales of these approved drugs during the forecast period.

Covid Recovery Analysis

Due to the COVID-19 pandemic in 2020, vendors had to decrease production capacity for certain interstitial cystitis drugs, such as immunosuppressants, because of reduced demand for managing symptoms. Nevertheless, the market bounced back in 2021, as healthcare centers resumed treatment for interstitial cystitis and pharmaceutical companies resumed clinical trials for interstitial cystitis drugs. Additionally, the growth of the regional market will be driven by ongoing developments by vendors operating in the region. As a result of these factors, it is expected that the market will experience positive growth during the forecast period.

Key Players in Interstitial Cystitis Drugs Market

There is high competition in the interstitial cystitis drugs market. Among several market players, the organization Allergan stands out among the competitors due to technological innovation and its on-point marketing strategy.

Allergan- The company offers interstitial cystitis (IC) drugs such as Enablex. Also, the company acquires, develops, manufactures, and markets brand-name drugs and medical devices in the areas of medical aesthetics, eye care, the central nervous system, and gastroenterology.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

Technavio’s report consists of a holistic analysis of the key development Analysis, development stage, pipeline analysis, FDA approval, market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge.

Interstitial Cystitis Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.

Key Interstitial Cystitis Drugs Market Driver

Bladder pain and lower urinary tract symptoms are common features of interstitial cystitis, a condition that affects many individuals, particularly women. According to a 2018 article by Muhammad Shahid et al. published in the National Center for Biotechnology Information (NCBI), over 3-8 million women and 1-4 million, men are diagnosed with interstitial cystitis annually in the US. Females are more likely to be affected by this condition, which is often linked to comorbidities like allergies, fibromyalgia, and endometriosis. In the UK, around 400,000 individuals have interstitial cystitis, with women accounting for 90% of cases. The Centers for Disease Control and Prevention (CDC) report a prevalence rate of 1.0 to 5.1 people per 100,000 for interstitial cystitis. Consequently, the high prevalence of interstitial cystitis is projected to propel market growth in the forecast period.

Significant Interstitial Cystitis Drugs Market Trend

Increasing approval for drugs is a primary trend in the market. The sole bladder instillation drug approved by the FDA for interstitial cystitis is Dimethyl sulfoxide (DMSO). According to researchers, more than half of patients reported improvement after receiving once-a-week treatments for six weeks. DMSO is occasionally combined with other medications and functions by relaxing the pelvic and bladder muscles to increase bladder capacity. This therapy is becoming more widely recognized as a more effective approach to treating interstitial cystitis. Besides dimethyl sulfoxide, other drugs have been introduced by vendors operating in the market. For example, in April, Kyorin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN, launched "Zymso Intravesical Solution" 50% for interstitial cystitis. The rising number of drug launches is expected to propel the market growth during the forecast period.

Major Interstitial Cystitis Drugs Market Challenge

Side effects of available medications is one of the major set back of the market. ELMIRON and RIMSO-50 (dimethyl sulfoxide) are the primary treatment options for interstitial cystitis due to their demonstrated safety and effectiveness in human clinical trials. However, long-term use of these drugs can result in severe side effects, despite their high therapeutic value. ELMIRON may cause nausea, diarrhea, gastric distress, and temporary hair loss, while RIMSO-50 can cause skin reactions, dry skin, headache, diarrhea, constipation, breathing problems, vision problems, and allergic reactions. The administration of RIMSO-50 also results in a garlic-like odor that persists for several hours.

Additionally, many off-label drugs, such as hydroxyzine, heparin, and amitriptyline, are frequently used to manage interstitial cystitis symptoms. Nonetheless, these drugs also have significant side effects. Amitriptyline, for example, can cause drowsiness, constipation, breathing problems, and swelling of the face, lips, tongue, and throat. In January 2022, a lawsuit was filed against Johnson and Johnson (J and J), its subsidiary Janssen Pharmaceuticals, and others in the United States for eye damage caused by the prolonged use of Elmiron to treat interstitial cystitis. Thus, the adverse effects linked to currently available drugs are anticipated to restrict market growth throughout the forecast period.

To know more about drivers, trends, and challenges download the sample reports

Key Interstitial Cystitis Drugs Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Interstitial Cystitis Drugs Market Customer Landscape

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by Type (Oral therapy and Intravesical therapy), Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), and Geography (North America, Europe, Asia, and Rest of World (ROW)).

Type Outlook (USD Million, 2017 - 2027)
- Oral therapy
- Intravesical therapy

Distribution Channel Outlook (USD Million, 2017 - 2027)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies

Region Outlook (USD Million, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- ROW
  - Argentina
  - Australia
  - Rest of the World

Interstitial Cystitis Drugs Market Scope
Report Coverage	Details
Page number	160
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 5.9%
Market growth 2023-2027	USD 369.58 million
Market structure	Fragmented
YoY growth 2022-2023(%)	5.26
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 35%
Key countries	US, UK, Germany, Japan, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Allergan, Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, Cadila Healthcare Ltd., Eli Lilly and Co., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd., Mission Pharmacal Co., Perrigo Co. Plc, Pfizer Inc., Purdue Pharma LP, Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Interstitial Cystitis Drugs Market Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the Interstitial cystitis (IC) drugs market between 2023 and 2027
Precise estimation of the size of the interstitial cystitis drugs market size and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Vendor landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on vendor position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of interstitial cystitis drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global interstitial cystitis drugs market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global interstitial cystitis drugs market 2017 - 2021 ($ million)

4.2 Type Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million)

4.3 Distribution channel Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Type - Market share 2022-2027 (%)

6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type

6.3 Oral therapy - Market size and forecast 2022-2027
- Exhibit 34: Chart on Oral therapy - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Oral therapy - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Oral therapy - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Oral therapy - Year-over-year growth 2022-2027 (%)

6.4 Intravesical therapy - Market size and forecast 2022-2027
- Exhibit 38: Chart on Intravesical therapy - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Intravesical therapy - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Intravesical therapy - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Intravesical therapy - Year-over-year growth 2022-2027 (%)

6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
- Exhibit 43: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 44: Data Table on Distribution Channel - Market share 2022-2027 (%)

7.2 Comparison by Distribution Channel
- Exhibit 45: Chart on Comparison by Distribution Channel
- Exhibit 46: Data Table on Comparison by Distribution Channel

7.3 Hospital pharmacies - Market size and forecast 2022-2027
- Exhibit 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
- Exhibit 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)

7.4 Retail pharmacies - Market size and forecast 2022-2027
- Exhibit 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)

7.5 Online pharmacies - Market size and forecast 2022-2027
- Exhibit 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
- Exhibit 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)

7.6 Market opportunity by Distribution Channel
- Exhibit 59: Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 61: Chart on Market share by geography 2022-2027 (%)
- Exhibit 62: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 63: Chart on Geographic comparison
- Exhibit 64: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 UK - Market size and forecast 2022-2027
- Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.9 Germany - Market size and forecast 2022-2027
- Exhibit 89: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 90: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 91: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.10 Japan - Market size and forecast 2022-2027
- Exhibit 93: Chart on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 94: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 95: Chart on Japan - Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on Japan - Year-over-year growth 2022-2027 (%)

9.11 China - Market size and forecast 2022-2027
- Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 101: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 102: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 103: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 104: Overview on factors of disruption

11.4 Industry risks
- Exhibit 105: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 106: Vendors covered

12.2 Market positioning of vendors
- Exhibit 107: Matrix on vendor position and classification

12.3 Allergan
- Exhibit 108: Allergan - Overview
- Exhibit 109: Allergan - Product / Service
- Exhibit 110: Allergan - Key offerings

12.4 Amneal Pharmaceuticals Inc.
- Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
- Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
- Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
- Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
- Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus

12.5 Astellas Pharma Inc.
- Exhibit 116: Astellas Pharma Inc. - Overview
- Exhibit 117: Astellas Pharma Inc. - Product / Service
- Exhibit 118: Astellas Pharma Inc. - Key offerings

12.6 Bayer AG
- Exhibit 119: Bayer AG - Overview
- Exhibit 120: Bayer AG - Business segments
- Exhibit 121: Bayer AG - Key news
- Exhibit 122: Bayer AG - Key offerings
- Exhibit 123: Bayer AG - Segment focus

12.7 Cadila Healthcare Ltd.
- Exhibit 124: Cadila Healthcare Ltd. - Overview
- Exhibit 125: Cadila Healthcare Ltd. - Business segments
- Exhibit 126: Cadila Healthcare Ltd. - Key offerings
- Exhibit 127: Cadila Healthcare Ltd. - Segment focus

12.8 Eli Lilly and Co.
- Exhibit 128: Eli Lilly and Co. - Overview
- Exhibit 129: Eli Lilly and Co. - Product / Service
- Exhibit 130: Eli Lilly and Co. - Key offerings

12.9 Johnson and Johnson
- Exhibit 131: Johnson and Johnson - Overview
- Exhibit 132: Johnson and Johnson - Business segments
- Exhibit 133: Johnson and Johnson - Key news
- Exhibit 134: Johnson and Johnson - Key offerings
- Exhibit 135: Johnson and Johnson - Segment focus

12.10 Kyorin Pharmaceutical Co. Ltd.
- Exhibit 136: Kyorin Pharmaceutical Co. Ltd. - Overview
- Exhibit 137: Kyorin Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 138: Kyorin Pharmaceutical Co. Ltd. - Key offerings

12.11 Perrigo Co. Plc
- Exhibit 139: Perrigo Co. Plc - Overview
- Exhibit 140: Perrigo Co. Plc - Business segments
- Exhibit 141: Perrigo Co. Plc - Key news
- Exhibit 142: Perrigo Co. Plc - Key offerings
- Exhibit 143: Perrigo Co. Plc - Segment focus

12.12 Pfizer Inc.
- Exhibit 144: Pfizer Inc. - Overview
- Exhibit 145: Pfizer Inc. - Product / Service
- Exhibit 146: Pfizer Inc. - Key news
- Exhibit 147: Pfizer Inc. - Key offerings

12.13 Seikagaku Corp.
- Exhibit 148: Seikagaku Corp. - Overview
- Exhibit 149: Seikagaku Corp. - Business segments
- Exhibit 150: Seikagaku Corp. - Key offerings
- Exhibit 151: Seikagaku Corp. - Segment focus

12.14 Sun Pharmaceutical Industries Ltd.
- Exhibit 152: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 153: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 154: Sun Pharmaceutical Industries Ltd. - Key offerings

12.15 Taro Pharmaceutical Industries Ltd.
- Exhibit 155: Taro Pharmaceutical Industries Ltd. - Overview
- Exhibit 156: Taro Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 157: Taro Pharmaceutical Industries Ltd. - Key offerings

12.16 Teva Pharmaceutical Industries Ltd.
- Exhibit 158: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 159: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 160: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 161: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 162: Teva Pharmaceutical Industries Ltd. - Segment focus

12.17 Viatris Inc.
- Exhibit 163: Viatris Inc. - Overview
- Exhibit 164: Viatris Inc. - Business segments
- Exhibit 165: Viatris Inc. - Key offerings
- Exhibit 166: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 167: Inclusions checklist
- Exhibit 168: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 169: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 170: Research methodology
- Exhibit 171: Validation techniques employed for market sizing
- Exhibit 172: Information sources

13.5 List of abbreviations
- Exhibit 173: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

interstitial cystitis drugs market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis